Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021
JAMA Dermatology · 01.11.2023 · 159 (11) · 1213
DOI: 10.1001/jamadermatol.2023.3256 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift JAMA Dermatology, erschienen am 01.11.2023. Verfasst von Neel M Helvind und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery, Copenhagen University Hospital: Herlev and Gentofte, Herlev, Denmark. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance To ensure optimal treatment and surveillance of patients with melanoma, knowledge of the clinical stage-specific risk of recurrence, mortality, and recurrence patterns across the American Joint Committee on Cancer Eighth Edition ( AJCC8 ) substages is needed.
Objective
To estimate stage-specific recurrence and melanoma-specific mortality rates, assess absolute stage-specific risks of recurrence and mortality, and describe stage-specific recurrence patterns, including conditional rates.
Design
Retrospective cohort study of prospectively collected nationwide population-based registry data.
Setting
Nationwide, population-based cohort study.
Participants
The 25 720 Danish patients, 18 years or older, diagnosed with first-time stage IA to IV cutaneous melanoma between January 1, 2008, and December 31, 2019, were included and followed up from time of primary treatment until December 31, 2021. Exposures First diagnosis of stage IA to IV cutaneous melanoma. Main Outcomes Stage-specific cumulative incidence of recurrence and melanoma-specific mortality, melanoma-specific recurrence-free survival, and assessed absolute stage-specific risks of recurrence and melanoma-specific mortality. Secondary outcomes were stage-specific recurrence patterns, including conditional rates, and melanoma-specific survival.
Results
We followed up 25 720 patients for a median of 5.9 years (95% CI, 58.9-59.3 years). Mean age was 59.1 years (95% CI, 58.9-59.3 years). Patients with stage IIB to IIC melanoma were older, had more comorbidities at diagnosis, and had the lowest rate of pathologic staging by sentinel node biopsy (81.6%-87.4%). A total of 10.6% of patients developed recurrence; first recurrence included distant recurrence, alone or with synchronous locoregional recurrence, in 56.6% of patients. We found a comparable risk of recurrence in stages IIIA and IIB (29.7% vs 33.2%) and in stages IIIB and IIC (35.9% vs 36.8%), respectively. Melanoma-specific mortality was comparable between stages IIIA and IIA (13.0% vs 13.6%) and between stages IIIB and IIB (18.4% vs 22.0%), respectively. These risk patterns persisted in cause-specific hazards models. Conclusions and Relevance This nationwide, population-based cohort study found that the increasing stages of the current AJCC8 staging system do not accurately reflect an increasing risk of recurrence and mortality in melanoma. The high proportion of distant recurrences suggests that hematogenous spread is a more common metastatic pathway than previously assumed, and surveillance with routine functional/cross-sectional imaging should be considered for stages IIB to IV. Future efforts should be put toward developing new tools for risk stratification and determining the survival effect of routine imaging in surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Plastic Surgery, Copenhagen University Hospital: Herlev and Gentofte, Herlev, Denmark.
- Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital: Herlev and Gentofte, Herlev, Denmark.
- National Center for Cancer Immune Therapy, Copenhagen University Hospital: Herlev and Gentofte, Herlev, Denmark.
- Department of Oncology, Copenhagen University Hospital: Herlev and Gentofte, Herlev, Denmark.
- Department of General and Plastic Surgery, Vejle Hospital, Vejle, Denmark.
- Department of Plastic Surgery, Zealand University Hospital Roskilde, Roskilde, Denmark.
Zitieren
APA
Helvind, N. M., Brinch-Møller Weitemeyer, M., Chakera, A. H., Hendel, H. W., Ellebæk, E., Svane, I. M., Kjærskov, M. W., Bojesen, S., Skyum, H., Petersen, S. K., Bastholt, L., Johansen, C., Bidstrup, P. E., & Hölmich, L. R. (2023). Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021. JAMA Dermatology, 159(11), 1213. https://doi.org/10.1001/jamadermatol.2023.3256
Vancouver
Helvind NM, Brinch-Møller Weitemeyer M, Chakera AH, Hendel HW, Ellebæk E, Svane IM, et al. Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021. JAMA Dermatology. 2023;159(11):1213. doi:10.1001/jamadermatol.2023.3256
BibTeX
@article{Helvind2023,
author = {Helvind, Neel M and Brinch-Møller Weitemeyer, Marie and Chakera, Annette H and Hendel, Helle W and Ellebæk, Eva and Svane, Inge Marie and Kjærskov, Mette W and Bojesen, Sophie and Skyum, Helle and Petersen, Søren K and Bastholt, Lars and Johansen, Christoffer and Bidstrup, Pernille E and Hölmich, Lisbet R},
title = {Stage-Specific Risk of Recurrence and Death From Melanoma in Denmark, 2008-2021},
journal = {JAMA Dermatology},
year = {2023},
volume = {159},
number = {11},
pages = {1213},
doi = {10.1001/jamadermatol.2023.3256}
}
EUVIMED